Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study

Basit Öğe Kaydı
dc.authorid0000-0002-0443-6966
dc.authorid0000-0001-7934-7039
dc.authorid0000-0003-2715-4002
dc.contributor.authorBilici, Ahmet
dc.contributor.authorUysal, Mükremin
dc.contributor.authorMenekşe, Serkan
dc.contributor.authorAkın, Semih
dc.contributor.authorYıldız, Fatih
dc.contributor.authorTuran, Merve
dc.contributor.authorSezgin Göksu, Sema
dc.contributor.authorBeypınar, İsmail
dc.contributor.authorSakalar, Teoman
dc.contributor.authorDeğirmenci, Mustafa
dc.contributor.authorErdem, Dilek
dc.contributor.authorBaşaran, Gül
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorAvcı, Nilüfer
dc.contributor.authorTural, Deniz
dc.contributor.authorSakin, Abdullah
dc.contributor.authorTürker, Sema
dc.contributor.authorDemir, Atakan
dc.contributor.authorTemiz, Süleyman
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorDoğan, Mutlu
dc.contributor.authorTanrıverdi, Özgür
dc.contributor.authorBilgetekin, İrem
dc.contributor.authorYeşil Çınkır, Havva
dc.contributor.authorAçıkgöz, Özgür
dc.contributor.authorPaydaş, Semra
dc.contributor.authorUslu, Rüçhan
dc.contributor.authorTurhal, Serdar
dc.date.accessioned2023-01-10T13:00:49Z
dc.date.available2023-01-10T13:00:49Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2?) metastatic breast cancer (MBC) patients in real-life settings. Methods: Overall, 204 HR+, HER2? MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results: The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion: We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER ? MBC patients.
dc.identifier.citationBilici, A., Uysal, M., Menekşe, S., Akın, S., Yıldız, F., Turan, M. ... Turhal, S. (2022). Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study. Cancer Investigation, 40(2), 199-209. https://dx.doi.org/10.1080/07357907.2021.2017952
dc.identifier.doi10.1080/07357907.2021.2017952
dc.identifier.endpage209
dc.identifier.issn0735-7907
dc.identifier.issn1532-4192
dc.identifier.issue2
dc.identifier.pmid34894960
dc.identifier.scopus2-s2.0-85121803055
dc.identifier.scopusqualityQ2
dc.identifier.startpage199
dc.identifier.urihttps://dx.doi.org/10.1080/07357907.2021.2017952
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10281
dc.identifier.volume40
dc.identifier.wos000734258300001en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBilici, Ahmet
dc.institutionauthorÖlmez, Ömer Fatih
dc.institutionauthorAçıkgöz, Özgür
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.ispartofCancer Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectEverolimus
dc.subjectExemestane
dc.subjectMetastatic Breast Cancer
dc.subjectHormone Receptor-Positive
dc.subjectHER Negative
dc.subjectEfficacy
dc.titleReal-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Bilici-Ahmet-2022.pdf
Boyut:
1.72 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu